ARS Pharmaceuticals Provides Commercial and Financial Updates
No new commercial formulary additions or coverage decisions issued for neffy® (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion
No new commercial formulary additions or coverage decisions issued for neffy® (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future inclusion
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.